{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:13:20Z","timestamp":1789827200841,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bone.2026.117835","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:17:24Z","timestamp":1770884244000},"page":"117835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Under-prescribed and underutilized: National trends in osteoporosis medication use after fragility fracture"],"prefix":"10.1016","volume":"206","author":[{"given":"Harsh","family":"Wadhwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelin J.","family":"Isakoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole S.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Henry","family":"Goodnough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius A.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2026.117835_bb0005","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00198-016-3894-y","article-title":"Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures","volume":"28","author":"Harvey","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2026.117835_bb0010","doi-asserted-by":"crossref","first-page":"385","DOI":"10.5435\/00124635-200411000-00003","article-title":"Recommendations for optimal care of the fragility fracture patient to reduce the risk of future fracture","volume":"12","author":"Bouxsein","year":"2004","journal-title":"J. Am. Acad. Orthop. Surg."},{"key":"10.1016\/j.bone.2026.117835_bb0015","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/gerona\/glt092","article-title":"Epidemiology of fracture risk with advancing age","volume":"68","author":"Ensrud","year":"2013","journal-title":"J. Gerontol. Ser. A"},{"key":"10.1016\/j.bone.2026.117835_bb0020","series-title":"Osteoporosis: Assessing the Risk of Fragility Fracture","year":"2017"},{"key":"10.1016\/j.bone.2026.117835_bb0025","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-149-6-200809160-00007","article-title":"Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians","volume":"149","author":"Qaseem","year":"2008","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bone.2026.117835_bb0030","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician\u2019s guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2026.117835_bb0035","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrendo.2011.146","article-title":"Antiresorptive therapies for osteoporosis: a clinical overview","volume":"8","author":"Chen","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bone.2026.117835_bb0040","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/bph.15024","article-title":"Overview of treatment approaches to osteoporosis","volume":"178","author":"Langdahl","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bone.2026.117835_bb0045","doi-asserted-by":"crossref","first-page":"707","DOI":"10.20945\/2359-3997000000566","article-title":"Anabolic therapy for osteoporosis: update on efficacy and safety","volume":"66","author":"Bandeira","year":"2022","journal-title":"Arch. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2026.117835_bb0050","doi-asserted-by":"crossref","first-page":"416","DOI":"10.14245\/ns.2347256.628","article-title":"Comparison of the clinical efficacy of anabolic agents and bisphosphonates in the patients with osteoporotic vertebral fracture: systematic review and meta-analysis of randomized controlled trials","volume":"21","author":"Jeon","year":"2024","journal-title":"Neurospine"},{"key":"10.1016\/j.bone.2026.117835_bb0055","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10800","article-title":"Anabolic and antiresorptive osteoporosis treatment: trends, costs, and sequence in a commercially insured population, 2003\u20132021","volume":"7","author":"Wadhwa","year":"2023","journal-title":"JBMR Plus"},{"key":"10.1016\/j.bone.2026.117835_bb0060","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.eprac.2021.06.015","article-title":"Meta-analysis of clinical fracture risk reduction of antiosteoporosis drugs: direct and indirect comparisons and meta-regressions","volume":"27","author":"Albert","year":"2021","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.bone.2026.117835_bb0065","doi-asserted-by":"crossref","first-page":"464","DOI":"10.5435\/JAAOS-D-23-00932","article-title":"Forgetting the frail: national trends in vitamin D prescription after fragility fracture-a large insurance claims database study","volume":"32","author":"Liu","year":"2024","journal-title":"J. Am. Acad. Orthop. Surg."},{"key":"10.1016\/j.bone.2026.117835_bb0070","series-title":"MarketScan Medicare Supplemental Database, Version 4.0. Redivis","author":"Stanford Center for Population Health Sciences (PHS)","year":"2025"},{"key":"10.1016\/j.bone.2026.117835_bb0075","series-title":"MarketScan Commercial Database, Version 4.0. Redivis","author":"Stanford Center for Population Health Sciences (PHS)","year":"2025"},{"key":"10.1016\/j.bone.2026.117835_bb0080","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00198-015-3249-0","article-title":"Disparities in osteoporosis treatments","volume":"27","author":"Liu","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2026.117835_bb0085","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s00198-018-4553-2","article-title":"Low rates of osteoporosis treatment after hospitalization for hip fracture in Hawaii","volume":"29","author":"Nguyen","year":"2018","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2026.117835_bb0090","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00774-019-01067-z","article-title":"Coding and prescription rates of osteoporosis are low among distal radius fracture patients in Japan","volume":"38","author":"Saka","year":"2020","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2026.117835_bb0095","series-title":"StatPearls","article-title":"Bisphosphonate","author":"Ganesan","year":"2025"},{"key":"10.1016\/j.bone.2026.117835_bb0100","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.117835_bb0105","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2026.117835_bb0110","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2026.117835_bb0115","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2026.117835_bb0120","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/ijms20010083","article-title":"Anabolic therapies in osteoporosis and bone regeneration","volume":"20","author":"Russow","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bone.2026.117835_bb0125","doi-asserted-by":"crossref","first-page":"750","DOI":"10.5534\/wjmh.200099","article-title":"Gender differences in osteoporosis: a single-center observational study","volume":"39","author":"De Martinis","year":"2021","journal-title":"World J. Mens Health"},{"key":"10.1016\/j.bone.2026.117835_bb0130","doi-asserted-by":"crossref","first-page":"382","DOI":"10.14740\/jocmr2970w","article-title":"Gender disparities in osteoporosis","volume":"9","author":"Alswat","year":"2017","journal-title":"J. Clin. Med. Res."},{"issue":"21","key":"10.1016\/j.bone.2026.117835_bb0135","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMcp2307353","article-title":"Postmenopausal osteoporosis","volume":"389","author":"Walker","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2026.117835_bb0140","unstructured":"What is Own the Bone?, AOA Own the Bone (n.d.). https:\/\/www.ownthebone.org\/what-is-otb\/ (accessed July 11, 2025)."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632822600061X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632822600061X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:58:16Z","timestamp":1773147496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S875632822600061X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":28,"alternative-id":["S875632822600061X"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2026.117835","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Under-prescribed and underutilized: National trends in osteoporosis medication use after fragility fracture","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2026.117835","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117835"}}